US20080108151A1 - Process for (A) Separating Biological Ligands From Dilute Solutions and (B) Conducting An Immunochromatographic Assay Thereof Employing Superparamagnetic Particles Throughout - Google Patents

Process for (A) Separating Biological Ligands From Dilute Solutions and (B) Conducting An Immunochromatographic Assay Thereof Employing Superparamagnetic Particles Throughout Download PDF

Info

Publication number
US20080108151A1
US20080108151A1 US11/928,903 US92890307A US2008108151A1 US 20080108151 A1 US20080108151 A1 US 20080108151A1 US 92890307 A US92890307 A US 92890307A US 2008108151 A1 US2008108151 A1 US 2008108151A1
Authority
US
United States
Prior art keywords
particles
ligand
sample
target
superparamagnetic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/928,903
Inventor
Roger Piasio
Nathan Turner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Diagnostics Scarborough Inc
Original Assignee
Binax Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Binax Inc filed Critical Binax Inc
Priority to US11/928,903 priority Critical patent/US20080108151A1/en
Publication of US20080108151A1 publication Critical patent/US20080108151A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983Viruses
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54326Magnetic particles
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366Apparatus specially adapted for solid-phase testing
    • G01N33/54386Analytical elements
    • G01N33/54387Immunochromatographic test strips
    • G01N33/54388Immunochromatographic test strips based on lateral flow
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/558Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2446/00Magnetic particle immunoreagent carriers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2446/00Magnetic particle immunoreagent carriers
    • G01N2446/20Magnetic particle immunoreagent carriers the magnetic material being present in the particle core
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2446/00Magnetic particle immunoreagent carriers
    • G01N2446/80Magnetic particle immunoreagent carriers characterised by the agent used to coat the magnetic particles, e.g. lipids
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/805Test papers
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/81Packaged device or kit
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/97Test strip or test slide
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00Chemistry: analytical and immunological testing
    • Y10S436/806Electrical property or magnetic property
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/25Chemistry: analytical and immunological testing including sample preparation
    • Y10T436/25375Liberation or purification of sample or separation of material from a sample [e.g., filtering, centrifuging, etc.]

Definitions

  • metallic particles having superparamagnetic properties to concentrate biological ligands present in small amounts in large volumes of aqueous fluids, including fluids of mammalian origin such as urine.
  • These metallic particles are often of large size (typically in the order of 1-5 ⁇ m or larger in average mean diameter) such that they cannot move, or do not move sufficiently readily, through the matrices used for either flow-through tests or lateral flow immunochromatographic (“ICT”) tests such as those commonly used currently in many commercially available diagnostic tests for identifying disease causative pathogens.
  • ICT lateral flow immunochromatographic
  • Particles heretofore used as tags for detecting a biological ligand are usually quite small. As already noted, this is especially true where rapid “flow-through” or lateral flow matrices having narrow pores are employed as solid phase substrates. Particularly in the lateral flow ICT format, particles used as detection markers must be small enough to migrate through the pores of the matrices and reach the immobilized binding partner of the biological ligand being detected.
  • the present invention is based on the discovery that there is a class of superparamagnetic particles which are small enough to function as tags for detection of biological ligands in ICT test formats where solid porous matrices are employed and also have a sufficiently large magnetic moment to function effectively as ligand concentration adjuvants.
  • the capability of using the same particles for concentration and separation of a target ligand from a large volume of liquid and as tags for a qualitative ligand identification test or a similar test that not only identifies but quantifies the amount of ligand enables a significant increase in the sensitivity of the pre-assay concentration step.
  • the separation of the target ligand from interfering or inhibitory substances that may be present in the original sample is enhanced, the awkward need for removing a magnetic label is avoided and so is the equally awkward need for introducing a second label.
  • the present invention utilizes superparamagnetic subunits of 1-30 nm in average mean diameter, such as ferrofluid subparticles, which are mixed with bovine serum albumin (“BSA”) or a similar biologically and magnetically non-interfering substance capable of coating and covering such particles, whereby they form BSA-coated ferrofluid particles which spontaneously agglomerate to masses each containing a number of ferrofluid subunit “cores” or nuggets, each completely surrounded by BSA.
  • BSA bovine serum albumin
  • BSA-ferrofluid agglomerates have been found to be highly effective, at overall particle average mean diameters of at least about 100 nm ranging up to about 450 nm, and at times even higher, (1) as agents from concentrating and separating out target biological ligands from large liquid volumes in which they are initially present in trace amounts and (2) as tags for enabling detection of these target ligands, for identity confirmation purposes and/or for quantification in ICT-format assays.
  • FIG. 1 hereof is a plot of magnetic signal measured in millivolts (mV) against Respiratory Syncytial Virus (“RSV”) lysate in milligrams per milliliter at sample volumes of 0.1 ml., 1.0 ml. and 10.0 ml., respectively.
  • mV millivolts
  • RSV Respiratory Syncytial Virus
  • the superparamagnetic material used in the investigative work described herein i.e. ferrofluid core subunits of 1-30 nm diameter dispersed in a magnetically and biochemically inactive matrix of BSA—can be substituted as to ferrofluid by any other metallic subunits of this size range that exhibit superparamagnetic properties, including metals and metallic oxides which exhibit spinel structure alone or in combinations with one another.
  • ferrofluid core subunits of 1-30 nm diameter dispersed in a magnetically and biochemically inactive matrix of BSA can be substituted as to ferrofluid by any other metallic subunits of this size range that exhibit superparamagnetic properties, including metals and metallic oxides which exhibit spinel structure alone or in combinations with one another.
  • other materials that are magnetically inactive and in themselves biochemically unreactive with the target ligand may readily be substituted for BSA.
  • the procedure for concentration of a target molecule in an aqueous medium renders it necessary that the BSA-superparamagnetic core agglomerates having a composite particle diameter of at least about 100 nm be first coated with a material which is a binding partner for the target molecule.
  • the coated superparamagnetic particles are then immersed in the fluid and incubated for a period of at least 15, and often 30-40 or more, minutes. Complexes of superparamagnetic particles and target ligand are thereby formed. These complexes are sequestered from the bulk of liquid sample by exposure to the gradient of a magnetic field.
  • the liquid is then removed by aspiration, decanting or any other convenient method and the particles are washed and dispersed in a volume of a suitable buffer that is smaller than the volume of the original sample.
  • the target molecule on their outer surface binds to its binding partner in the immovable stripe, causing superparamagnetic particles to accumulate along the stripe.
  • immovable striping of binding partner for the target molecule in multiple lines, spaced apart from one another along the end of the strip remote from the sample receiving end may be appropriate to ensure efficient capture of the target ligand in this assay.
  • the magnetic signal of the superparamagnetic tag on the capture line or lines in millivolts is read in a suitable instrument.
  • the instrument used for the work shown in the ensuing specific examples was a Magnetic Assay Reader IV unit obtained from Quantum Design, Inc., San Diego, Calif.
  • This unit is especially designed to be compatible with small volume assay formats, such as those which exhibit the end result as a line or lines of accumulated magnetic tag material. Because of the permeability of the magnetic field of the superparamagnetic tag, signal due to any analyte immobilized to the capture line is read as a single magnetic mass. This is in contrast to readings obtained from optical inspection which detect only the surface appearance of the capture line. According to the manufacturer, the magnetic reading is linear with respect to the mass of magnetic material on the capture line through at least four orders of magnitude. The construction of standard curves correlating measured magnetic signal to target ligand amount is readily achievable by methodology that is well known in the art.
  • auxiliary magnetizable columns, filters or screens, or the addition of nickel powder to the sample it may at times be necessary to make use of auxiliary magnetizable columns, filters or screens, or the addition of nickel powder to the sample, to facilitate complete separation from the sample and from unbound particles, of the low mass of superparamagnetic material actually bound to target molecules.
  • RSV respiratory syncytial virus
  • This example as presented illustrates the efficacy and feasibility of the superparamagnetic particles of this invention, when coated with an appropriate biological ligand such as the antibody employed in the work underlying this example, and thus enabling extraction of a biological ligand from a dilute solution in which it occurs and thereby also concentrating the ligand. It also illustrates the efficacy and practicality involved in using the same superparamagnetic particles as tags for the biological ligand in an ensuing ICT assay.
  • Particles of approximately 100 nm average mean diameter composed of ferrofluid subunits, each of 1-30 nm average mean diameter, distributed in an enveloping matrix of BSA were coated with anti- Legionella pneumophila serogroup 1 antibodies which had been purified as described in copending U.S. application Ser. No. 09/139,720. Equal amounts of the resulting conjugate were added to all four of the samples and allowed to incubate for 15 minutes. Each sample was then exposed to the gradient of a strong magnetic field as in Example 1.
  • the sample having no added bacteria gave a negative reading of ⁇ 248.4 mV, which is believed attributable to the presence in the sample of particulate that was not broken down.
  • the sample with added bacteria gave a reading of 375 mV.
  • the remaining two samples were each washed 3 times with 500 ml. of the buffer and then reconstituted to 100 ⁇ l and run in the same manner in an identical ICT test, to that of the first two samples.
  • the magnetic moments of the capture lines of each of the respective test strips were read in the Quantum Design instrument.
  • the washed sample having no added bacteria gave a reading of 8.5 mV.
  • the washed sample with added bacteria gave a reading of 161.8 mV.
  • the example supports the broad concept of superparamagnetic alloy separating the target ligand—in this instance the O-polysaccharide antigen of Legionella pneumophila serogroup 1—from a liquid sample, using superparamagnetic particles, followed by conducting an immunoassay using the same supermagnetic label for detection.

Abstract

Superparamagnetic (“SPM”) subunits of 1-30 nm average mean diameter (e.g. ferro fluid) subparticles are treated with a magnetically noninterfering substance capable of coating and covering them (e.g, BSA) and they spontaneously form agglomerates of about 100 nm to about 450 nm or higher average mean diameter and are then used to form complexes with target biological ligands such as viruses, contained in large volumes of liquid. The complexes are subjected to the gradient intensity of a strong magnetic field, and excess liquid is removed, where upon an immunochromatographic assay is conducted to determine the identity and/or amount of target ligand present, in which operation SPM particles that bonded to the ligand function as tags for ligand detection.

Description

    INTRODUCTION
  • This application is a continuation of U.S. patent application Ser. No. 10/044,920 filed Jan. 15, 2002, now U.S. Pat. No. ______. This invention relates to using the same superparamagnetic particles, as more particularly described hereinafter, to concentrate biological substances believed to be sparsely present in large volumes of fluids and as labelling agents for detecting the quantity of the same biological molecules present in a fluid sample.
  • BACKGROUND OR THE INVENTION
  • Heretofore it has become common to use metallic particles having superparamagnetic properties to concentrate biological ligands present in small amounts in large volumes of aqueous fluids, including fluids of mammalian origin such as urine. These metallic particles are often of large size (typically in the order of 1-5 μm or larger in average mean diameter) such that they cannot move, or do not move sufficiently readily, through the matrices used for either flow-through tests or lateral flow immunochromatographic (“ICT”) tests such as those commonly used currently in many commercially available diagnostic tests for identifying disease causative pathogens. In an instance where such tests are to follow the initial concentration step, removal of the superparamagnetic particles used for concentration is necessary, followed by adding a target specific conjugate labelled with a chemiluminescent, fluorescent or radioactive tag, or a tag such as colloidal latex particles, colloidal gold, or another colloidal metal which couples to the biological ligand and aids in the detection thereof. The need to remove superparamagnetic particles used in ligand concentration and then subject the concentrated ligand to an identification or quantification assay often poses problems. For example, quantification of the small amount of biological ligand obtained by concentration is rendered inaccurate if even a tiny fragment of concentrated ligand clings to the particles used for concentration; by the same token, incomplete removal of a small fragment of a magnetic particle may disrupt a qualitative identification of the concentrated sample by setting up an interaction with the labelling agent chosen for use in the subsequent identification test. Even in cases where superparamagnetic particles are employed to concentrate biological ligands present in a large volumes of fluid and the nature of the subsequent identification procedure renders separation of the superparamagnetic particles unnecessary, these particles have heretofore been viewed in the art as irrelevant to the subsequent identification step.
  • Large sized superparamagnetic particles have been preferred for ligand concentration work, because their large size (in the order of 1 to 5 μm or more) increases the mass of material bound to the target ligand and allows the gradient field of a fixed magnet to effect separation with ease. Much smaller particles have been used in some instances but often the low mass of magnetic material that they impart to their target, requires the introduction of magnetizable columns, filters or screens as an aid to separating the target molecules from the sample.
  • Particles heretofore used as tags for detecting a biological ligand (regardless of whether it has been subjected to a first concentration step) are usually quite small. As already noted, this is especially true where rapid “flow-through” or lateral flow matrices having narrow pores are employed as solid phase substrates. Particularly in the lateral flow ICT format, particles used as detection markers must be small enough to migrate through the pores of the matrices and reach the immobilized binding partner of the biological ligand being detected.
  • The present invention is based on the discovery that there is a class of superparamagnetic particles which are small enough to function as tags for detection of biological ligands in ICT test formats where solid porous matrices are employed and also have a sufficiently large magnetic moment to function effectively as ligand concentration adjuvants. The capability of using the same particles for concentration and separation of a target ligand from a large volume of liquid and as tags for a qualitative ligand identification test or a similar test that not only identifies but quantifies the amount of ligand enables a significant increase in the sensitivity of the pre-assay concentration step. At the same time, the separation of the target ligand from interfering or inhibitory substances that may be present in the original sample is enhanced, the awkward need for removing a magnetic label is avoided and so is the equally awkward need for introducing a second label.
  • BRIEF DESCRIPTION OF THE INVENTION
  • The present invention utilizes superparamagnetic subunits of 1-30 nm in average mean diameter, such as ferrofluid subparticles, which are mixed with bovine serum albumin (“BSA”) or a similar biologically and magnetically non-interfering substance capable of coating and covering such particles, whereby they form BSA-coated ferrofluid particles which spontaneously agglomerate to masses each containing a number of ferrofluid subunit “cores” or nuggets, each completely surrounded by BSA. These BSA-ferrofluid agglomerates have been found to be highly effective, at overall particle average mean diameters of at least about 100 nm ranging up to about 450 nm, and at times even higher, (1) as agents from concentrating and separating out target biological ligands from large liquid volumes in which they are initially present in trace amounts and (2) as tags for enabling detection of these target ligands, for identity confirmation purposes and/or for quantification in ICT-format assays.
  • BRIEF DESCRIPTION OF THE DRAWING
  • FIG. 1 hereof is a plot of magnetic signal measured in millivolts (mV) against Respiratory Syncytial Virus (“RSV”) lysate in milligrams per milliliter at sample volumes of 0.1 ml., 1.0 ml. and 10.0 ml., respectively.
  • DETAILED DESCRIPTION OF THE INVENTION
  • The vistas opened by the use of this invention are best appreciated from a consideration of the fact that the commercially available ICT assays described in the copending, commonly assigned U.S. patent application Ser. No. 09/139,720 filed Aug. 25, 1998 and Ser. No. 09/397,110, now U.S. Pat. No. 6,824,997 filed Sep. 16, 1999 as a continuation in part of Ser. No. 09/156,488 filed Sep. 18, 1998, now abandoned, which are both highly sensitive and specific for identifying the presence of particular disease-causing bacteria, are successfully run with a few drops of test fluid—in the order of 100 microliters of urine, for example. Bacteria molecules, however, are large in comparison to the molecules of, e.g., viruses and various biochemical substances, the presence or concentration of which may be indicative of a disease state or another abnormal condition in a human patient.
  • These smaller molecules often are widely dispersed in samples of mammalian fluid, such as urine, with the result that the sample size adequate to enable detection of particular bacteria in the urine of a person suffering from a disease of which those bacteria are causative, is too dilute to insure that smaller disease-causing molecules will be equally readily detectable.
  • By affording a means of concentrating the smaller molecules in a liquid sample prior to assaying for them, one is enabled to detect and, if desired, quantify, the presence in, e.g., human urine, of molecules that—if run in the assay format described in the aforementioned copending applications, without preconcentration, could not be detected with high sensitivity and specificity and might not be detectable at all. Experience to date with pre-assay concentration using superparamagnetic particles composed of ferrofluid 1-30 nm diameter subunits distributed in a BSA matrix, said composite particles having average mean diameters of between at least about 100 nm and about 450 nm and coated with an antibody to the target molecule which attracts the target molecule and couples thereto, thereby effecting the desired concentration upon exposure to the gradient of a magnetic field, when followed by an ICT assay for the target molecule which assay employs the aforesaid superparamagnetic particles as tags in the assay, has demonstrated a gain of approximately 2 logarithms of sensitivity to the target molecule over results heretofore attainable with methods wherein it was attempted to perform a conventional ICT assay for the target molecule on the original sample without concentration.
  • The superparamagnetic material used in the investigative work described herein—i.e. ferrofluid core subunits of 1-30 nm diameter dispersed in a magnetically and biochemically inactive matrix of BSA—can be substituted as to ferrofluid by any other metallic subunits of this size range that exhibit superparamagnetic properties, including metals and metallic oxides which exhibit spinel structure alone or in combinations with one another. As already noted other materials that are magnetically inactive and in themselves biochemically unreactive with the target ligand may readily be substituted for BSA.
  • The procedure for concentration of a target molecule in an aqueous medium (including a mammalian bodily fluid such as urine, blood, saliva, sputum, etc.) renders it necessary that the BSA-superparamagnetic core agglomerates having a composite particle diameter of at least about 100 nm be first coated with a material which is a binding partner for the target molecule. The coated superparamagnetic particles are then immersed in the fluid and incubated for a period of at least 15, and often 30-40 or more, minutes. Complexes of superparamagnetic particles and target ligand are thereby formed. These complexes are sequestered from the bulk of liquid sample by exposure to the gradient of a magnetic field. The liquid is then removed by aspiration, decanting or any other convenient method and the particles are washed and dispersed in a volume of a suitable buffer that is smaller than the volume of the original sample. An ICT strip of nitrocellulose or other bibulous material upon which a stripe of binding partner for the target molecule—which may be the same one used in the concentration step or a different one, depending upon the functionality of the target molecule—has been immovably bound to the capture zone area, contained in a “dipstick” ICT device format, is immersed in the buffered dispersion of superparamagnetic particles complexes. Upon migration of these particle complexes along the strip, the target molecule on their outer surface binds to its binding partner in the immovable stripe, causing superparamagnetic particles to accumulate along the stripe. Experience has shown that immovable striping of binding partner for the target molecule in multiple lines, spaced apart from one another along the end of the strip remote from the sample receiving end, may be appropriate to ensure efficient capture of the target ligand in this assay. The magnetic signal of the superparamagnetic tag on the capture line or lines in millivolts, is read in a suitable instrument. The instrument used for the work shown in the ensuing specific examples was a Magnetic Assay Reader IV unit obtained from Quantum Design, Inc., San Diego, Calif.
  • This unit is especially designed to be compatible with small volume assay formats, such as those which exhibit the end result as a line or lines of accumulated magnetic tag material. Because of the permeability of the magnetic field of the superparamagnetic tag, signal due to any analyte immobilized to the capture line is read as a single magnetic mass. This is in contrast to readings obtained from optical inspection which detect only the surface appearance of the capture line. According to the manufacturer, the magnetic reading is linear with respect to the mass of magnetic material on the capture line through at least four orders of magnitude. The construction of standard curves correlating measured magnetic signal to target ligand amount is readily achievable by methodology that is well known in the art.
  • It is anticipated that, for concentrating target molecules present in mammalian bodily fluids, such as, e.g. urine, saliva, blood, etc. at very high dilution levels, it may at times be necessary to make use of auxiliary magnetizable columns, filters or screens, or the addition of nickel powder to the sample, to facilitate complete separation from the sample and from unbound particles, of the low mass of superparamagnetic material actually bound to target molecules.
  • The following examples, which are illustrative only and in no sense limiting, illustrate how the invention works in practice:
  • EXAMPLE 1
  • A partially purified viral lysate of respiratory syncytial virus (“RSV”) obtained from Chemicon (Catalog #Ag857, Lot 21031072) was diluted in an aqueous buffer of pH 7.8+0.1 having the following composition:
      • Tris base—24.22 grams per liter (g.p.l.)
      • Triton X-100—10 ml./liter
      • Tween 20—10 ml./liter
      • N-tetradecyl-N, N-dimethyl-3-ammonio-1-propane sulfonate—20.0 g.p.l.
      • Sodium azide—0.2 g.p.l.
      • Water added to make 1 liter
        The resulting dilution contained 0.05 mg/ml. of RSV lysate. Samples of 0.1 ml., 1 ml. and 10 ml., respectively of this dilution were carefully withdrawn after thorough mixing. To each of the 3 samples there was then added 5 microliters of approximately 250 nm average mean diameter superparamagnetic particles consisting of ferrofluid subunits of 1-30 nm diameter embedded in and each separately surrounded by BSA, which composite particles had been previously coated with anti-RSV monoclonal antibody obtained from Viro Stat, Inc. (Catalog #0631, Lot RM286). The mixture of the coated superparamagnetic particles and buffered viral lysate was in each instance thoroughly mixed and allowed to incubate for 30 minutes at room temperature on a blood bag rotator platform. Each sample was then exposed to the gradient magnetic field intensity produced by a strong rare earth permanent magnet and held stationary for at least 30 minutes, thereby concentrating the superparamagnetic conjugate and any bound RSV lysate and sequestering them in the area of greatest field intensity proximal to the magnet. In each instance the supernatant was then removed by aspiration and 100 microliters of the above-described buffer was then added.
  • Each of the three resulting sample concentrates was thoroughly mixed and placed in contact with a 22.5 mm wide nitrocellulose lateral flow ICT membrane (purchased from Millipore Corp. and identified as HF07504, Lot RK 000231) upon which had earlier been immovably striped across its width in the “capture” zone (located in the area most remote from the point of sample introduction) the same anti-RSV-monoclonal antibody referred to above. The contact with the nitrocellulose membrane, in each instance was initiated through an absorbent bridging pad, whereby the magnetic complex with analyte bound thereto was caused to migrate laterally through the strip to the capture line, along which magnetic conjugate bound to the viral lysate analyte bound, but magnetic conjugate free of viral lysate did not bind and was allowed to flow into an absorbent zone positioned after the capture line. In each instance the magnetic signal in millivolts of the capture line was read with the Quantum Design instrument referred to above. The exact procedure was repeated for each sample using run buffer alone, without the present of RSV viral lysate, as a negative control. The measured results are shown in the following Table 1:
    TABLE #1
    Measured Signal in mV
    RSV Lysate Concentration 0.1 ml 1.0 ml 10 ml.
    in mg 1 ml sample sample sample
    0 7.3 17.6 12.60
    0.05 41.2 218.2 408.20
  • The results set forth in Table 1 are graphed in FIG. 1 hereof, wherein the intensity of magnetically induced signal is represented as a straight line function of RSV lysate concentration in mg./ml. for each sample volume assayed.
  • The signal to noise ratio and the detection limit in mg./ml. for each sample were calculated and the results appear in the following Table 2:
    TABLE #2
    RSV Lysate Concentration 0.05 mg. per ml.
    Signal to Noise Ratio Detection Limit in mg./ml.
    0.1 ml. sample 5.6 0.027
    1.0 ml. sample 12.5 0.012
     10 ml. sample 32.4 0.0046
  • Later work has shown that the total sensitivity of antigenic detection for each sample volume can be increased if multiple fixed stripes of antibody are applied to the ICT membrane, each spaced apart from one another along the sample flow path and the total magnetic moment of these capture lines is measured.
  • This example as presented illustrates the efficacy and feasibility of the superparamagnetic particles of this invention, when coated with an appropriate biological ligand such as the antibody employed in the work underlying this example, and thus enabling extraction of a biological ligand from a dilute solution in which it occurs and thereby also concentrating the ligand. It also illustrates the efficacy and practicality involved in using the same superparamagnetic particles as tags for the biological ligand in an ensuing ICT assay.
  • EXAMPLE 2
  • This example involves a possible use of the superparamagnetic particles described herein in an experimental ICT test for quantifying Legionella pneumophila serogroup 1 in environmental water. The present commercially available test is described in copending, commonly assigned U.S. application Ser. No. 09/458,998 filed Dec. 10, 1999 as a continuation-in-part of copending, commonly assigned U.S. application Ser. No. 09/139,770 filed Aug. 25, 1998.
  • In this experiment, two 100 ml. samples of cooling tower water were drawn at Hood Dairy, Portland, Me. and held at temperature of 2-8° C. To one of these samples was added sufficient Legionella pneumophila serogroup 1 bacteria to enrich the sample bacteria content by 95 colony-forming units (“CFU”) per ml. Both samples were subjected to a filtration concentration on a small pore membrane as described in detail in copending U.S. application Ser. No. 09/458,998. The particulate retained on the membrane was recovered on a swab in each instance and was reconstituted to a sample volume of 200 μl with a buffer composition composed of aqueous 0.05 M Tris HCl and 2.5% Tween 20 having a pH of 7.0±0.1. Each sample was then carefully split into two portions. All four resulting samples were of equal volume.
  • Particles of approximately 100 nm average mean diameter composed of ferrofluid subunits, each of 1-30 nm average mean diameter, distributed in an enveloping matrix of BSA were coated with anti-Legionella pneumophila serogroup 1 antibodies which had been purified as described in copending U.S. application Ser. No. 09/139,720. Equal amounts of the resulting conjugate were added to all four of the samples and allowed to incubate for 15 minutes. Each sample was then exposed to the gradient of a strong magnetic field as in Example 1. One sample having no added Legionella pneumophila serogroup 1 bacteria and one sample having 95 CFu/ml of added bacteria were immediately subjected to an ICT test performed with a dipstick style lateral flow device comprising a nitrocellulose membrane pretreated by the application of a fixed stripe of purified anti-Legionella pneumophila serogroup 1 antibodies at the end of the strip most remote from the point of sample-introduction. The test strips and sample in each instance were not washed; once the samples had migrated to the end of the nitrocellulose membrane, the conductivities in millivolts (mV) of the capture lines were read by the Quantum Design instrument referred to above. The sample having no added bacteria gave a negative reading of −248.4 mV, which is believed attributable to the presence in the sample of particulate that was not broken down. The sample with added bacteria (95 CFU/ml) gave a reading of 375 mV.
  • The remaining two samples were each washed 3 times with 500 ml. of the buffer and then reconstituted to 100 μl and run in the same manner in an identical ICT test, to that of the first two samples. The magnetic moments of the capture lines of each of the respective test strips were read in the Quantum Design instrument. The washed sample having no added bacteria gave a reading of 8.5 mV. The washed sample with added bacteria gave a reading of 161.8 mV.
  • The example supports the broad concept of superparamagnetic alloy separating the target ligand—in this instance the O-polysaccharide antigen of Legionella pneumophila serogroup 1—from a liquid sample, using superparamagnetic particles, followed by conducting an immunoassay using the same supermagnetic label for detection.
  • Those skilled in the art will recognize many opportunities for making use of the particles and methods referred to herein beyond the possibilities explicitly disclosed. It is therefore intended that the scope of this invention be limited only by the appended claims.

Claims (1)

1. A process for (1) separating a target biological ligand suspected of being present in dilute concentration in an aqueous fluid and (2) ascertaining whether said target ligand is present, which process comprises the steps of
a) coating with a first biological binding partner for said target biological ligand a group of superparamagnetic particles, which particles have an average mean diameter of at least about 100 nm and are each composed of superparamagnetic subunits, which subunits have an average mean diameter of 1-30 nm and are separately spaced from one another within a covering matrix of nonmetallic, non-magnetic material that is compatible, but non reactive, with said biological ligand and its first biological binding partner,
b) immersing the coated superparamagnetic particles from step (a) in a sample of said aqueous fluid which is suspected of containing said target biological ligand and allowing said particles and said fluid to incubate for a time sufficient to allow the target biological ligand, if present, to react with its first biological binding partner coated on said particles, thereby forming complexes,
c) exposing said particles to the gradient of a magnetic field, whereby said they acquire a magnetic charge and are attracted to one another,
d) removing said particles from said fluid with a permanent magnet,
e) washing said particles
f) releasing said magnetic field and removing said particles,
g) adding to said particles a small volume of an aqueous buffer to form a dispersion of said particles in said buffer
h) applying said dispersion from step (g) to the sample receiving end of an immunochromatographic (“ICT”) device comprising a strip of bibulous material having at least one immovable stripe of a second binding partner for said ligand affixed permanently thereto at a position near the end of said strip that is opposite its sample receiving end,
(i) allowing said dispersion to migrate along said strip and contact said at least one immovable stripe of a second binding partner for said biological ligand, whereby target biological ligand on the surface of said particles binds to its second binding partner on said immovable stripe, and
(j) observing whether a mass of the metallic material from said particles, indicative of the presence of said target ligand in said sample, appears along said immovable stripe.
US11/928,903 2002-01-15 2007-10-30 Process for (A) Separating Biological Ligands From Dilute Solutions and (B) Conducting An Immunochromatographic Assay Thereof Employing Superparamagnetic Particles Throughout Abandoned US20080108151A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/928,903 US20080108151A1 (en) 2002-01-15 2007-10-30 Process for (A) Separating Biological Ligands From Dilute Solutions and (B) Conducting An Immunochromatographic Assay Thereof Employing Superparamagnetic Particles Throughout

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/044,920 US7018849B2 (en) 2002-01-15 2002-01-15 Process for (A) separating biological/ligands from dilute solutions and (B) conducting an immunochromatographic assay thereof employing superparamagnetic particles throughtout
US11/295,486 US7358099B2 (en) 2002-01-15 2005-12-07 Process for (A) separating biological/ligands from dilute solutions and (B) conducting an immunochromatographic assay thereof employing superparamagnetic particles throughout
US11/928,903 US20080108151A1 (en) 2002-01-15 2007-10-30 Process for (A) Separating Biological Ligands From Dilute Solutions and (B) Conducting An Immunochromatographic Assay Thereof Employing Superparamagnetic Particles Throughout

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US11/295,486 Continuation US7358099B2 (en) 2002-01-15 2005-12-07 Process for (A) separating biological/ligands from dilute solutions and (B) conducting an immunochromatographic assay thereof employing superparamagnetic particles throughout

Publications (1)

Publication Number Publication Date
US20080108151A1 true US20080108151A1 (en) 2008-05-08

Family

ID=21935040

Family Applications (3)

Application Number Title Priority Date Filing Date
US10/044,920 Expired - Lifetime US7018849B2 (en) 2002-01-15 2002-01-15 Process for (A) separating biological/ligands from dilute solutions and (B) conducting an immunochromatographic assay thereof employing superparamagnetic particles throughtout
US11/295,486 Expired - Lifetime US7358099B2 (en) 2002-01-15 2005-12-07 Process for (A) separating biological/ligands from dilute solutions and (B) conducting an immunochromatographic assay thereof employing superparamagnetic particles throughout
US11/928,903 Abandoned US20080108151A1 (en) 2002-01-15 2007-10-30 Process for (A) Separating Biological Ligands From Dilute Solutions and (B) Conducting An Immunochromatographic Assay Thereof Employing Superparamagnetic Particles Throughout

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US10/044,920 Expired - Lifetime US7018849B2 (en) 2002-01-15 2002-01-15 Process for (A) separating biological/ligands from dilute solutions and (B) conducting an immunochromatographic assay thereof employing superparamagnetic particles throughtout
US11/295,486 Expired - Lifetime US7358099B2 (en) 2002-01-15 2005-12-07 Process for (A) separating biological/ligands from dilute solutions and (B) conducting an immunochromatographic assay thereof employing superparamagnetic particles throughout

Country Status (3)

Country Link
US (3) US7018849B2 (en)
AU (1) AU2003210511A1 (en)
WO (1) WO2003060472A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009155384A1 (en) * 2008-06-17 2009-12-23 Georgia Tech Research Corporation Superparamagnetic nanoparticles for removal of cells, pathogens or viruses
WO2011045436A1 (en) * 2009-10-16 2011-04-21 Åmic AB An assay method and devices involving the use of magnetic particles

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030092029A1 (en) * 2001-06-06 2003-05-15 Lee Josephson Magneitc-nanoparticle conjugates and methods of use
US7418485B2 (en) * 2003-04-24 2008-08-26 Nokia Corporation System and method for addressing networked terminals via pseudonym translation
US20050071419A1 (en) * 2003-09-26 2005-03-31 Lewontin Stephen Paul System, apparatus, and method for providing Web services using wireless push
US20050071423A1 (en) * 2003-09-26 2005-03-31 Jaakko Rajaniemi System, apparatus, and method for providing Web services on mobile devices
US7781228B2 (en) * 2005-04-07 2010-08-24 Menon & Associates, Inc. Magnetic resonance system and method to detect and confirm analytes
JP5021629B2 (en) * 2005-05-09 2012-09-12 ザ ジェネラル ホスピタル コーポレイション Sensors based on water relaxation
AU2006284832B2 (en) 2005-08-31 2011-06-02 T2 Biosystems Inc. NMR device for detection of analytes involving magnetic particles
US20070166730A1 (en) * 2006-01-19 2007-07-19 Menon & Associates, Inc. Magnetic resonance system and method to detect and confirm analytes
US7547557B2 (en) * 2006-06-13 2009-06-16 Quantum Design, Inc. Directed-flow assay device
AU2007317787B2 (en) * 2006-11-08 2012-07-12 T2 Biosystems, Inc. NMR systems for in vivo detection of analytes
WO2009026251A1 (en) * 2007-08-17 2009-02-26 The General Hospital Corporation Detecting ions and measuring ion concentrations
JP2010540929A (en) 2007-09-28 2010-12-24 ティツー・バイオシステムズ・インコーポレーテッド Diagnosis with NMR equipment using plastic sample containers
WO2009061481A1 (en) * 2007-11-06 2009-05-14 T2 Biosystems, Inc. Small magnet and rf coil for magnetic resonance relaxometry
CA2741550C (en) 2008-10-29 2018-12-04 T2 Biosystems, Inc. Nmr detection of coagulation time
US8409807B2 (en) 2010-10-22 2013-04-02 T2 Biosystems, Inc. NMR systems and methods for the rapid detection of analytes
EP2630517B1 (en) 2010-10-22 2016-03-16 T2 Biosystems, Inc. Nmr systems and methods for the rapid detection of analytes
US8563298B2 (en) 2010-10-22 2013-10-22 T2 Biosystems, Inc. NMR systems and methods for the rapid detection of analytes
CN103917658B (en) 2011-07-13 2016-09-21 T2生物系统公司 For monitoring the NMR method that clot is formed
WO2013043858A1 (en) 2011-09-21 2013-03-28 T2 Biosystems, Inc. Nmr methods for endotoxin analysis
EP2839038B1 (en) 2012-04-20 2019-01-16 T2 Biosystems, Inc. Compositions and methods for detection of candida species
WO2014089346A1 (en) 2012-12-07 2014-06-12 T2 Biosystems, Inc. Methods for monitoring tight clot formation
ES2656117T3 (en) * 2014-07-31 2018-02-23 Betelgeux, S. L. Method and apparatus for the detection of microorganisms
US11519016B2 (en) 2016-01-21 2022-12-06 T2 Biosystems, Inc. NMR methods and systems for the rapid detection of bacteria
US10458974B2 (en) 2017-06-09 2019-10-29 Optimum Imaging Diagnostics LLC Universal testing system for quantitative analysis

Citations (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4230685A (en) * 1979-02-28 1980-10-28 Northwestern University Method of magnetic separation of cells and the like, and microspheres for use therein
US4267234A (en) * 1978-03-17 1981-05-12 California Institute Of Technology Polyglutaraldehyde synthesis and protein bonding substrates
US4297337A (en) * 1979-04-13 1981-10-27 Corning Glass Works Solid-phase immunoassays using magnetic glass
US4452773A (en) * 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US4554088A (en) * 1983-05-12 1985-11-19 Advanced Magnetics Inc. Magnetic particles for use in separations
US4628037A (en) * 1983-05-12 1986-12-09 Advanced Magnetics, Inc. Binding assays employing magnetic particles
US4672040A (en) * 1983-05-12 1987-06-09 Advanced Magnetics, Inc. Magnetic particles for use in separations
US4795698A (en) * 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
US4965007A (en) * 1988-05-10 1990-10-23 Eastman Kodak Company Encapsulated superparamagnetic particles
US5252493A (en) * 1986-09-22 1993-10-12 Nippon Telegraph And Telephone Corporation Laser magnetic immunoassay method and apparatus therefor
US5385707A (en) * 1988-12-28 1995-01-31 Stefan Miltenyi Metal matrices for use in high gradient magnetic separation of biological materials and method for coating the same
US5445971A (en) * 1992-03-20 1995-08-29 Abbott Laboratories Magnetically assisted binding assays using magnetically labeled binding members
US5445970A (en) * 1992-03-20 1995-08-29 Abbott Laboratories Magnetically assisted binding assays using magnetically labeled binding members
US5492814A (en) * 1990-07-06 1996-02-20 The General Hospital Corporation Monocrystalline iron oxide particles for studying biological tissues
US5512332A (en) * 1985-10-04 1996-04-30 Immunivest Corporation Process of making resuspendable coated magnetic particles
US5597531A (en) * 1985-10-04 1997-01-28 Immunivest Corporation Resuspendable coated magnetic particles and stable magnetic particle suspensions
US5770388A (en) * 1989-12-22 1998-06-23 Dade Behring Marburg Gmbh Method of separation employing magnetic particles and second medium
US5916539A (en) * 1993-03-02 1999-06-29 Silica Gel Ges. M.B.H. Superparamagnetic particles, process for producing the same and their use
US6007690A (en) * 1996-07-30 1999-12-28 Aclara Biosciences, Inc. Integrated microfluidic devices
US6120856A (en) * 1995-06-07 2000-09-19 Immunivest Corporation Coated, resuspendable magnetically responsive, transition metal oxide particles and method for the preparation thereof
US6479305B2 (en) * 1998-09-18 2002-11-12 Hitachi, Ltd. Semiconductor device manufacturing method
US20030040124A1 (en) * 2000-03-17 2003-02-27 Laborde Ronald T. Immunochromatographic assay method and apparatus

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8408127D0 (en) * 1984-03-29 1984-05-10 Nyegaard & Co As Contrast agents
FI850481A0 (en) 1985-02-06 1985-02-06 Labsystems Oy FOERFARANDE FOER BESTAEMNING AV MOTMEDEL ELLER ANTIGENER.
JP2001509891A (en) * 1997-01-30 2001-07-24 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング Methods for immunological measurement of analytes
AU3487800A (en) 1999-02-11 2000-08-29 University Of Southern California Enzyme-linked immuno-magnetic electrochemical biosensor

Patent Citations (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4267234A (en) * 1978-03-17 1981-05-12 California Institute Of Technology Polyglutaraldehyde synthesis and protein bonding substrates
US4230685A (en) * 1979-02-28 1980-10-28 Northwestern University Method of magnetic separation of cells and the like, and microspheres for use therein
US4297337A (en) * 1979-04-13 1981-10-27 Corning Glass Works Solid-phase immunoassays using magnetic glass
US4452773A (en) * 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US4554088A (en) * 1983-05-12 1985-11-19 Advanced Magnetics Inc. Magnetic particles for use in separations
US4628037A (en) * 1983-05-12 1986-12-09 Advanced Magnetics, Inc. Binding assays employing magnetic particles
US4672040A (en) * 1983-05-12 1987-06-09 Advanced Magnetics, Inc. Magnetic particles for use in separations
US5597531A (en) * 1985-10-04 1997-01-28 Immunivest Corporation Resuspendable coated magnetic particles and stable magnetic particle suspensions
US4795698A (en) * 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
US5512332A (en) * 1985-10-04 1996-04-30 Immunivest Corporation Process of making resuspendable coated magnetic particles
US5252493A (en) * 1986-09-22 1993-10-12 Nippon Telegraph And Telephone Corporation Laser magnetic immunoassay method and apparatus therefor
US4965007A (en) * 1988-05-10 1990-10-23 Eastman Kodak Company Encapsulated superparamagnetic particles
US5385707A (en) * 1988-12-28 1995-01-31 Stefan Miltenyi Metal matrices for use in high gradient magnetic separation of biological materials and method for coating the same
US5770388A (en) * 1989-12-22 1998-06-23 Dade Behring Marburg Gmbh Method of separation employing magnetic particles and second medium
US5492814A (en) * 1990-07-06 1996-02-20 The General Hospital Corporation Monocrystalline iron oxide particles for studying biological tissues
US5445971A (en) * 1992-03-20 1995-08-29 Abbott Laboratories Magnetically assisted binding assays using magnetically labeled binding members
US5445970A (en) * 1992-03-20 1995-08-29 Abbott Laboratories Magnetically assisted binding assays using magnetically labeled binding members
US5916539A (en) * 1993-03-02 1999-06-29 Silica Gel Ges. M.B.H. Superparamagnetic particles, process for producing the same and their use
US6120856A (en) * 1995-06-07 2000-09-19 Immunivest Corporation Coated, resuspendable magnetically responsive, transition metal oxide particles and method for the preparation thereof
US6007690A (en) * 1996-07-30 1999-12-28 Aclara Biosciences, Inc. Integrated microfluidic devices
US6479305B2 (en) * 1998-09-18 2002-11-12 Hitachi, Ltd. Semiconductor device manufacturing method
US20030040124A1 (en) * 2000-03-17 2003-02-27 Laborde Ronald T. Immunochromatographic assay method and apparatus
US6607922B2 (en) * 2000-03-17 2003-08-19 Quantum Design, Inc. Immunochromatographic assay method and apparatus

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009155384A1 (en) * 2008-06-17 2009-12-23 Georgia Tech Research Corporation Superparamagnetic nanoparticles for removal of cells, pathogens or viruses
US20110098623A1 (en) * 2008-06-17 2011-04-28 Georgia Tech Research Corporation Device and method of using superparamagnetic nanoparticles in treatment and removal of cells
WO2011045436A1 (en) * 2009-10-16 2011-04-21 Åmic AB An assay method and devices involving the use of magnetic particles
CN102753972A (en) * 2009-10-16 2012-10-24 阿米克股份公司 An assay method and devices involving the use of magnetic particles

Also Published As

Publication number Publication date
WO2003060472A3 (en) 2003-11-27
US20060094128A1 (en) 2006-05-04
AU2003210511A8 (en) 2003-07-30
AU2003210511A1 (en) 2003-07-30
US20030134434A1 (en) 2003-07-17
US7018849B2 (en) 2006-03-28
US7358099B2 (en) 2008-04-15
WO2003060472A2 (en) 2003-07-24

Similar Documents

Publication Publication Date Title
US7358099B2 (en) Process for (A) separating biological/ligands from dilute solutions and (B) conducting an immunochromatographic assay thereof employing superparamagnetic particles throughout
US4018886A (en) Diagnostic method and device employing protein-coated magnetic particles
JP4237267B2 (en) Magnetically assisted binding assay using magnetically responsive reagents
CN100501403C (en) Method for detecting analyte(s) using magnetic colloidal particles
US20070020700A1 (en) Lateral flow assay and device using magnetic particles
GB2045431A (en) Immunoassay utilising two particulate reagents
CA2324096A1 (en) Integrated assay device and methods of production and use
JP4482035B2 (en) Particle-based binding assays
US10732178B2 (en) Detection assays employing magnetic nanoparticles
WO2019088142A1 (en) Detection agent for bioassay and signal amplification method using same
US6479302B1 (en) Method for the immunological determination of an analyte
JP2007003410A (en) Measuring method of hemoglobin a1c, and measuring kit for hemoglobin a1c measurement
US20030124745A1 (en) Process for detecting or quantifying a biological reaction using superparamagnetic label
US20020123079A1 (en) Process for detecting or quantifying a biological rreaction using superparamagnetic label
JPH05504828A (en) Capillary flow device and dual capture assay method
JP2599175B2 (en) Laser magnetic immunoassay method and measuring apparatus, superparamagnetic label used for laser magnetic immunoassay, and method for producing the same
EP0861441B1 (en) Methods of capture and assay procedures
JP2007003412A (en) Biological measuring method
CN216718452U (en) Triple drug fluorescence immunoassay card
JP2005043049A (en) Method for detecting or determining quantitatively biological reaction using superparamagnetic labeling
JP4881077B2 (en) Immunochromatography
JPH02222836A (en) Method and test kit for increased visualization of reactant between substance specifically bonded and corresponding bonding substance
DE19547346A1 (en) Immunological determination of analytes
WO2001018235A2 (en) Lateral flow device with metal oxide indicator and assay method employing same
JP2001013146A (en) Test piece for immunochromatography

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION